Indole-3-PROpionic Acid Clinical Trials - a Pilot Study Part 2

Launched by GLOSTRUP UNIVERSITY HOSPITAL, COPENHAGEN · Jul 29, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a natural substance called indole-3-propionic acid (IPA) when taken as a supplement by healthy adults. Researchers want to see if taking IPA twice a day can help increase certain immune cells that protect the body from autoimmune diseases, boost a protein that supports brain health, and improve blood markers related to risks for conditions like diabetes and heart disease. The study will last 14 days, during which participants will take capsules containing either IPA or a placebo (a harmless inactive pill).

Healthy men and women between the ages of 18 and 65 who are physically and mentally well may be eligible to join. People with certain health conditions, recent antibiotic use, or who are pregnant or breastfeeding will not be able to participate. Participants will visit the clinic twice—once at the start and once at the end of the study—to provide blood, urine, and stool samples, have simple health checks, complete questionnaires, and share any side effects they notice. This study is not yet recruiting but aims to better understand how IPA might support immune and brain health in healthy adults.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Healthy women and men ≥18 and ≤65 years of age
• • Deemed mentally and physically able to participate
• Exclusion Criteria:
• • Diagnosis of gut-, heart-, liver-, kidney or immune-related disorders
• • Use of antibiotics within the last month
• • Pregnancy, lactation or childbirth within the last five months
• • Use of prescription medication